Neural Therapeutics Inc. (CSE:NURL)

Neural Therapeutics Financials Overview

Financials in millions CAD. Fiscal year is August - July.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jan 31, 2026	Jul 31, 2025	Jul 31, 2024	Jul 31, 2023	Jul 31, 2022
Operating Income Operating Income Growth	-0.89	-0.97	-0.65	-1.2	-0.74
Net Income Net Income Growth	-1.26	-1.03	-0.67	-1.08	-1.82
Earnings Per Share EPS Growth	-0.01	-0.01	-0.01	-0.03	-0.05
EPS Growth	-	-	-	-	-

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jan 31, 2026	Jul 31, 2025	Jul 31, 2024	Jul 31, 2023	Jul 31, 2022
Cash & Investments Cash & Investments Growth	0.06	0.17	0.07	0.27	0.37
Total Debt Total Debt Growth	0.8	0.74	0.38	0.14	-
Net Cash (Debt) Net Cash Growth	-0.74	-0.58	-0.32	0.13	0.37
Net Cash Growth	-	-	-	-64.04%	-
Net Cash Per Share Net Cash Per Share Growth	-0.01	-0.01	-0.01	0.00	0.01

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jan 31, 2026	Jul 31, 2025	Jul 31, 2024	Jul 31, 2023	Jul 31, 2022
Operating Cash Flow Operating Cash Flow Growth	-0.41	-0.32	-0.32	-0.53	-0.6
Free Cash Flow Free Cash Flow Growth	-0.41	-0.32	-0.32	-0.53	-0.6
Free Cash Flow Growth	-	-	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Jan 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 16, 2026

Data Sources Report a data error